Yousif Capital Management LLC Sells 285 Shares of CONMED Co. (NYSE:CNMD)

Yousif Capital Management LLC cut its position in shares of CONMED Co. (NYSE:CNMD) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,917 shares of the company’s stock after selling 285 shares during the period. Yousif Capital Management LLC’s holdings in CONMED were worth $816,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of CONMED by 93.6% in the 4th quarter. GAMMA Investing LLC now owns 726 shares of the company’s stock valued at $50,000 after purchasing an additional 351 shares during the period. CWM LLC raised its stake in CONMED by 36.1% during the third quarter. CWM LLC now owns 1,251 shares of the company’s stock worth $90,000 after acquiring an additional 332 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of CONMED by 41.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,656 shares of the company’s stock valued at $113,000 after acquiring an additional 485 shares during the period. nVerses Capital LLC boosted its stake in shares of CONMED by 566.7% in the 3rd quarter. nVerses Capital LLC now owns 2,000 shares of the company’s stock valued at $144,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of CONMED by 26.5% in the 3rd quarter. Blue Trust Inc. now owns 3,121 shares of the company’s stock worth $216,000 after purchasing an additional 653 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have weighed in on CNMD shares. Stifel Nicolaus upped their price objective on shares of CONMED from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Wells Fargo & Company dropped their price target on CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a report on Thursday, February 6th. Needham & Company LLC decreased their target price on CONMED from $97.00 to $91.00 and set a “buy” rating on the stock in a report on Thursday, February 6th. JPMorgan Chase & Co. cut CONMED from an “overweight” rating to a “neutral” rating and cut their price target for the company from $85.00 to $70.00 in a report on Thursday, February 6th. Finally, StockNews.com lowered shares of CONMED from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $77.20.

CONMED Price Performance

CONMED stock opened at $63.05 on Friday. The business’s 50-day simple moving average is $69.43 and its 200 day simple moving average is $69.93. The company has a quick ratio of 1.06, a current ratio of 2.27 and a debt-to-equity ratio of 1.01. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 1.05 and a beta of 1.46. CONMED Co. has a 12-month low of $61.05 and a 12-month high of $86.96.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.60%. As a group, research analysts anticipate that CONMED Co. will post 4.35 earnings per share for the current year.

CONMED Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date was Friday, December 20th. CONMED’s dividend payout ratio (DPR) is currently 18.87%.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.